Comparison of Sertraline with Rifampin for treatment of pruritus

Comparison of Sertraline with Rifampin for treatment of pruritus induced by cholestasis in patients with Hepatobiliary disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015062822956N1

Enrollment

Registered

2016-03-04

Start date

2015-10-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Primary sclerosing cholangitis. Condition 2: pruritus. Condition 3: Primary biliary cirrhosis. Calculus of bile duct with cholangitis Pruritus, unspecified Primary biliary cirrhosis

Interventions

Intervention 1: sertraline, 100 mg oral tablet, Once a day, for 4 weeks. Intervention 2: rifampin, 300 mg oral capsul, once a day, for 4 weeks.

Treatment - Drugs

sertraline, 100 mg oral tablet, Once a day, for 4 weeks

rifampin, 300 mg oral capsul, once a day, for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria: They should have psc or pbc disease; People have a moderate to severe degree itching; People to participate in the study, are satisfied. exclusion criteria: Unwillingness of patients to participate in study; More than 3-fold increase in liver enzymes and symptoms.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pruritus. Timepoint: before the intervention and after the fourth week measured. Method of measurement: Using visual analog (VAS).	—

Secondary

Measure	Time frame
Direct bilirubin. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;ALP. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;Total bilirubin. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;ALT. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;AST. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.	—

Measure

Time frame

Direct bilirubin. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;ALP. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;Total bilirubin. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;ALT. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.;AST. Timepoint: Before the intervention, and then every two weeks. Method of measurement: Using laboratory findings.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Ataei

Hamedan University of Medical Sciences

Dr_sa1742@yahoo.com+98 912 440 2319

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026